MedTrace Logo

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

NCT03037151 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-02-13

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection with or without human immunodeficiency virus (HIV) infection.

Conditions

  • Compensated Cirrhosis

Interventions

DRUG

Grazaoprevir/Elbasavir

treatment naive

DRUG

Grazaoprevir/Elbasavir/RBV

treatment experienced

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Anchalee Avihingsanon, MD, PhD · HIV-NAT, Thai Red Cross - AIDS Research Centre

  • Pisit Tangkijvanich, MD · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037151 on ClinicalTrials.gov